Is Clinical Pharmacy in Vein?
نویسندگان
چکیده
منابع مشابه
Professionalism ethics in pharmacy education: Do students have acceptable knowledge or it is a white paper in pharmacy education curriculum?
Dear Editor, In pharmacy, professionalism must containthe skills necessary to be a capable pharmacypractitioner. It seems that pharmacy studentsdo not become professionals after graduationfrom the pharmacy school. To be a professionalpharmacist, students should have a lifelongcommitment to the society and patients.Evolving professional knowledge, attitudesand behaviors is a critical step in pro...
متن کاملSocial Pharmacy and Clinical Pharmacy—Joining Forces
This commentary seeks to define the areas of social pharmacy and clinical pharmacy to uncover what they have in common and what still sets them apart. Common threats and challenges of the two areas are reviewed in order to understand the forces in play. Forces that still keep clinical and social pharmacy apart are university structures, research traditions, and the management of pharmacy servic...
متن کاملClinical Pharmacy in Iran: Where Do We Stand?
Since late 1960s, pharmacists in the USA and England have started a professional movement towards a more efficient presence in clinical wards of hospitals. A similar movement has started in developed European countries during the past decade. Pharmacists are convinced of the need for them to play their role as drug consultants and pharmacotherapy advisers to make decisions on drug therapy probl...
متن کاملClinical Pharmacy in Iran: Where Do We Stand?
Since late 1960s, pharmacists in the USA and England have started a professional movement towards a more efficient presence in clinical wards of hospitals. A similar movement has started in developed European countries during the past decade. Pharmacists are convinced of the need for them to play their role as drug consultants and pharmacotherapy advisers to make decisions on drug therapy probl...
متن کاملClinical pharmacy and clinical trials
CPC-148 Table 1 adalimumab infliximab ustekinumab Lost to follow-up 5% (1/20) 23.5% (4/17) 22% (2/9) Continuing treatment 40% (8/20) 29.4% (5/17) 67% (6/9) Withdrawal/ Discontinuation by doctor 5% (1/20) 5.9% (1/17) 11% (1/9) Discontinuation due to good response 20% (4/20) – – Change of treatment 30% (6/20) 41.2% (7/17) – The causes of the discontinuation/change of treatment were: Abstract CPC-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmacy Practice and Research
سال: 2003
ISSN: 1445-937X
DOI: 10.1002/jppr2003334256